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Abstract
Background: Vitamin D plays a role in cancer development and acts through the vitamin D receptor (VDR). Although
African-Americans have the lowest levels of serum vitamin D, there is a dearth of information on VDR gene polymorphisms
and breast cancer among African-Americans and Hispanics. This study examines whether VDR gene polymorphisms are
associated with breast cancer in these cohorts.
Methods: Blood was collected from 232 breast cancer patients (Cases) and 349 non-cancer subjects (Controls). Genotyping
for four polymorphic variants of VDR (FokI, BsmI, TaqI and ApaI) was performed using the PCR-RFLP method.
Results: An increased association of the VDR-Fok1 f allele with breast cancer was observed in African-Americans (OR = 1.9,
p = 0.07). Furthermore, the FbTA, FbtA and fbtA haplotypes were associated with breast cancer among African-Americans
(p,0.05). Latinas were more likely to have the VDR-ApaI alleles (Aa or aa) (p = 0.008). The VDR-ApaI aa genotype was
significantly associated with poorly-differentiated breast tumors (p = 0.04) in combined Cases. Kaplan-Meier survival analysis
showed decreased 5-year disease-free-survival (DFS) in breast cancer patients who had the VDR-Fok1 FF genotype (p,0.05).
The Cox regression with multivariate analysis revealed the independent predictor value of the VDR-FokI polymorphism for
DFS. The other three variants of VDR (BsmI, TaqI and ApaI) were not associated with disease outcome.
Conclusions: VDR haplotypes are associated with breast cancer in African-Americans, but not in Hispanic/Latinas. The VDR-
FokI FF genotype is linked with poor prognosis in African-American women with breast cancer.
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Introduction
Several studies have demonstrated a decrease in Vitamin D
receptor (VDR) expression in breast cancer cells compared to
normal breast cells [1]. Decreased levels of VDR in breast cancer
cells could be due to VDR gene polymorphisms [2], and/or DNA
methylation [3–5]. Alterations in VDR expression and activity
could lead to deregulation of Vitamin D uptake, metabolism, and
serum levels of biologically active Vitamin D.
VDR gene has multiple gene polymorphisms [6], and four
important single nucleotide polymorphisms (SNPs) in exon 2 and
39UTR region. These are VDR-FokI (rs2228570), VDR-BsmI
(rs1544410), VDR-TaqI (rs731236) and VDR-ApaI (rs7975232).
Functional studies have identified that the VDR-FokI polymor-
phism leads to a shorter VDR protein by altering a translation
initiation site [7,8]. Large meta-analyses have demonstrated a
significant association of the VDR FokI polymorphisms with
breast cancer [9,10], and other cancers across multiple ethnic
cohorts [11,12]. The functional role of VDR-BSMI, VDR-TaqI,
and VDR-ApaI, which are all located near the 39UTR region, are
not as clear. However, studies do suggest that these polymor-
phisms may alter the polyadenylation of the VDR mRNA
transcript, and thus affect mRNA stability [13]. Several studies
show contradictory results on these polymorphisms and risk for
breast cancer. Some studies found an association of breast cancer
with BsmI, TaqI and ApaI [14–18] polymorphisms while others
found no associations [19–21].
We have examined four VDR polymorphisms (FokI, TaqI,
BsmI, ApaI) in African-American and Hispanic women from
South Los Angeles and their association with breast cancer risk
and survival.
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Materials and Methods
Ethics Statement
This study, including the consent protocol, was approved by the
Charles R. Drew University of Science and Medicine Institutional
Review Board (Approval # 00-06-041-13). Written informed
consent was obtained from all participants.
Study Population
This is a retrospective cohort hospital-based study. Subjects
were selected from our current breast study database in the
Division of Cancer Research and Training, at Charles R. Drew
University of Medicine and Science. We selected 232 women with
breast cancer as Cases (115 African-Americans and 117 Hispanic/
Latinas), and 349 normal, healthy women as Controls (73 African-
Americans and 276 Latinas). Subjects were recruited between
1995 and 2007, and had documented personal history, clinical
history, and tumor pathology data.
VDR polymorphisms
Genomic DNA was extracted from buffy coat samples using the
Qiagen DNA extraction kit. Vitamin D receptor genotyping for all
four single-nucleotide polymorphic sites (SNPs) was done by the
PCR-RFLP method (polymerase chain reaction- restriction
fragment length polymorphism analysis). We used the following
flanking primers [16,21]. The BsmI polymorphism was detected
using one primer originating in exon 7 (Forward: 59-CAACCAA-
GACTACAAGTACCGCGTCAGTGA-39) and a second in
intron 8 (Reverse: 59-AACCAGCGGAAGAGGTCAAGGG-39),
amplifying an 823 base pair (bp) fragment spanning the BsmI site.
The ApaI and TaqI polymorphisms were detected using one
primer in intron 8 (Forward: 59- AGAGCATGGACAGGGAG-
CAAG- 39) and the other in exon 9 (Reverse: 59-GCAACTCCT-
CATGGCTGAGGTCTCA- 39), yielding a 745 bp fragment
spanning the ApaI and TaqI site. VDR-FokI polymorphic site
was amplified using following primers Forward -59GATGC-
CAGCTGGCCCTGGCACTG39 and Reverse – 59ATGGAAA-
CACCTTGCTTCTTCTCCCTC 39. PCR conditions were as
follows: denaturation at 94uC for 5 min, followed by 40 cycles of
PCR at 94uC (30 sec), 60uC–63.5uC (30 sec), and 72uC (30 sec).
Annealing temperature for BsmI, ApaI/TaqI and FokI PCR are
63.5uC, 61uC and 59.5uC, respectively. Following PCR, aliquots
of the amplified PCR products was digested with BsmI, ApaI,
TaqI and FokI in accordance with the manufacturer’s specifica-
tions (New England Biolabs, Beverly, MA, USA). The presence
(lowercase) or absence (uppercase) of the enzyme recognition site
was identified by ethidium bromide staining of fragments
separated in a 2% agarose gel. Genotypes were assigned as BB,
Bb, bb for the BsmI polymorphisms, AA, Aa, aa for the ApaI
polymorphisms, TT, Tt and tt for the TaqI polymorphisms and
FF, Ff and ff for the VDR-FokI polymorphisms. For the BsmI
cleaved PCR products, the single resultant fragment was 823 bp,
whereas the two resultant fragments were 648 bp and 175 bp. The
PCR products digested with TaqI enzyme resulted in fragments of
496 bp and 249 bp in the presence of the polymorphic cutting site.
PCR products digested with ApaI enzyme result in fragments of
531 bp and 214 bp in the presence of the polymorphic cutting site.
The PCR products of VDR-FokI polymorphism (273 bp) digested
with FokI enzyme result in 198 bp and 75 bp products in the
presence of restriction site.
Statistical Analysis
We used SPSS (ver 11.5) software to analyze our data. The
Pearson Chi-square test was used to determine the statistically
Table 1. Characteristics of Breast Cancer Cases and Controls.
Subject
Characteristics
African-
American Latina P-Value*
(N=188) (N=393)
Mean Age±SD
(Range)
Cases 5369 49611 0.006
Controls 51610 46610 0.001
P-Value** 0.13 0.003
Mean BMI±SD
(Range)
Cases 3469 3267 0.01
Controls 3568 3166 ,0.001
P-Value** 0.74 0.19
Cases Only
(N=232)
N (%) N (%)
ER/PR Status
ER/PR+ 60 (52) 54 (46) 0.24
ER/PR- 42 (37) 43 (37)
Unknown 13 (11) 20 (17)
HER2 Status
3+ 16 (14) 22 (19) 0.64
2+ 12 (10) 14 (12)
1+ 27 (24) 21 (18)
Negative 40 (35) 35 (30)
Unknown 20 (17) 25 (21)
Histology
Infiltrating
Ductal Carcinoma
72 (63) 72 (62) 0.77
Infiltrating
Lobular Carcinoma
20 (17) 15 (13)
Infiltrating
Adenocarcinoma
4 (4) 2 (2)
Infiltrating
Intraductal
Carcinoma
0 (0) 1 (1)
Ductal 0 (0) 1 (1)
Lobular 2 (2) 2 (2)
Unknown 17 (15) 24 (2)
Differentiation
Well 10 (9) 6 (5) 0.23
Moderately 33 (29) 30 (26)
Poorly 55 (48) 55 (47)
Unknown 17 (15) 26 (22)
Stage
0 7 (6) 8 (7) 0.05
I 23 (20) 8 (7)
II 46 (40) 47 (40)
III 22 (19) 29 (25)
IV 4 (4) 7 (6)
Unknown 13 (11) 18 (15)
*P-value,0.05 is significant.
**P-value assesses significance within the column. (P,0.05 is significant).
doi:10.1371/journal.pone.0057967.t001
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significant differences in frequency distribution of VDR genotypes
between Cases and Controls. If the Table had cells with a
frequency less than 5, Fisher’s exact test was utilized. The 2-sided
exact p-value,0.05 was considered statistically significant. The
deviation of distribution of VDR genotypes from Hardy-Weinberg
equilibrium (HWE) was estimated using the web tool HWE
Testing calculator, available online [22]. Associations between
each VDR polymorphism and breast cancer was estimated using
the Logistic Regression test at 95% confidence interval, and
controlled for age and BMI. For each polymorphic site, the wild
type genotype (FF, BB, AA, TT) was considered as the reference
based on published literature. We also performed analysis of
linkage disequilibrium (LD) between polymorphic sites in a locus,
to identify ‘‘clusters’’ of highly correlated sites based on LD
statistics. We calculated the haplotype frequencies and LD in
Cases and Controls using the Haplotype software package
available online [23,24].
Results
Table 1 shows the characteristics of subjects in the study. The
mean age of African-American Cases and Controls is 52.9 and
50.7 years, respectively, and for Hispanic/Latinas Cases and
Controls is 49.2 and 45.6 years, respectively. The mean BMI is
.30 kg/m‘2. Among Cases, the distribution of histopathological
characteristics between African-American and Hispanic women
with breast cancer was similar (Table 1), and approximately
,59.9% Cases had Stage I/II disease and 26.7% had Stage III/V
disease. The majority of our patients had infiltrating ductal
carcinoma (62.2%), moderately to poorly differentiated (.70%).
The VDR gene polymorphisms were genotyped in 188 African-
American and 393 Hispanics/Latina women. No deviation was
observed from Hardy-Weinberg equilibrium (HWE) in the
genotypic distribution of the VDR-FokI, VDR-BsmI and VDR-
ApaI polymorphisms in the study subjects. However, the VDR-
TaqI distribution was not within HWE. Further analysis identified
that the deviation of VDR-TaqI was contributed from Cases (p
allele = 0.75, q allele = 0.25, x2 = 13.52), but not from Controls (p
allele = 0.79, q allele = 0.21, x2 = 2.34) – data not shown.
Logistic regression analysis was also performed (adjusted for age
and BMI) and showed no significant association of breast cancer
with any of the VDR polymorphisms when all of the Cases were
Figure 1. Five-year disease free survival (DFS) of breast cancer patients in relation to VDR gene polymorphisms. Kaplan-Meier survival
curves were used to compare the 5-year DFS between the VDR gene polymorphisms in (a) VDR-FokI, (b) VDR-BsmI, (c) VDR-ApaI, and (d) VDR-TaqI.
The differences between the curves were estimated by log-rank test, where P,0.05 was considered statistically significant.
doi:10.1371/journal.pone.0057967.g001
Table 6. Relative Risk of worse Disease-Free-Survival in
relation to VDR gene polymorphisms (Multivariate Analysis).
Polymorphism RR* (95% CI) P-value
FokI
FF 1 (0.3–0.9) 0.05
Ff+ff 0.57
BsmI
BB 1 (0.3–1.9) 0.45
Bb+bb 0.67
ApaI
AA 1 (0.5–1.7) 0.80
Aa+aa 0.92
TaqI
TT 1 (0.7–2.4) 0.48
Tt+tt 1.3
*RR: Relative Risk adjusted for tumor characteristics and ethnicity.
doi:10.1371/journal.pone.0057967.t006
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pooled together (Table 2). However, when the analysis was
performed based on ethnic stratification of the African-American
and Hispanic/Latina subjects, the VDR-FokI Ff genotype
(OR=2.2, 95% CI= 0.95-5.1, p = 0.06) and the f allele
(OR=1.9, 95% CI= 0.9-3.7, p= 0.07) showed an increased
association with breast cancer among African-American subjects
(Table 2) compared with the Hispanic/Latina subjects. In the
Hispanic/Latina population, we found no significant difference in
the frequency distribution of the VDR genotypes between Cases
and Controls, and no association with any of the genotypes with
breast cancer based on logistic regression analysis (Table 2).
Haplotype analysis of the polymorphic variants produced 16
different haplotypes (Table 3). The FBTA (FokI-F, BsmI-B, TaqI-T
and ApaI-A) was the most common haplotype in Controls and
Hispanic/Latina Cases (Table 3). The most common haplotype in
African-American Cases was the FbTA haplotype (FokI-F, BsmI-b,
TaqI-T and ApaI-A). Several VDR-haplotypes were significantly
associated with breast cancer in the African-American cohort,
however, no association was observed between breast cancer and
VDR-haplotypes in the Hispanic/Latina cohort. Logistic regres-
sion analysis, using wild-type alleles (FBTA) as the reference
category, revealed that FbTA was 1.9 times higher (p = 0.02), FbtA
Table 7. Summary of Studies on Breast Cancer and VDR polymorphisms.
Reference Study design Ethnicity
No. of
Cases
No. of
Controls
Association between VDR polymorphism and breast
cancer
FokI BsmI TaqI ApaI
Curran, 1999 [16] Hospital Caucasian 135 110 n.s. n.s. a allele
Dunning, 1999 [27] Hospital/Population Caucasian 951 627 n.s.
Ingles, 2000 [14] Population Latinas 143 300 n.s. B allele
Bretherton-Watt, 2001
[28]
Hospital Caucasian 181 241 n.s. bb type
Guy, 2004 [17] Hospital Caucasian 398 427 n.s. bb type
Hefler, 2004 [29] Hospital/Population Caucasian 390 1,699 n.s
Chen, 2005 [30] Population Caucasian 1,234 1,676 ff type n.s.
Vande Vord, 2006 [31] Hospital Mixed 220 192 n.s.
Caucasian (50.3%)
AA(49.7%)
John, 2007 [32] Population Mixed 1,786 2,127 n.s. n.s. n.s.
Caucasian 596 646
AA 543 598
Hispanic 647 883
McCullough, 2007 [15] Population Caucasian 500 500 n.s. n.s. n.s. n.s.
Trabert, 2007 [21] Population Caucasian 1,143 987 bb type*
AA 488 448 n.s.
Abbas, 2008 [26] Population Caucasian 1,403 2,609 n.s. n.s.
Gapska, 2008 [33] Population Caucasian 800‘ 550 f allele n.s. n.s.
Sinotte, 2008 [34] Hospital/Population Caucasian 859 1,381 ff type n.s.
Barroso, 2008 [35] Hospital Caucasian 549 556 ff type# tt typea
McKay, 2009 [25] Population Caucasian 378 421 n.s. n.s.
AA 325 419 n.s. n.s.
Hispanic 318 378 n.s. n.s.
Asian 401 405 ff type Bb typea
Hawaiian 104 278 n.s. n.s.
Tang, 2009 [10] Meta-Analysis All ethnicities .5,000 .7,000 ff type n.s. n.s. n.s.
Raimondi, 2009 [9] Review All ethnicities 14,863 21,318 ff type n.s.
Rollinson, 2012 [19] Population Non-Hispanic White 1,527 1,599 n.s n.s.
Hispanic 791 922
Vadgama, 2012 Hospital AA 115 73 f vs. F, OR = 1.9,
p = 0.07
n.s. n.s. n.s.
Latina 117 267 n.s. n.s. n.s. n.s.
AA: African-American.
*for postmenopausal women.
‘for early-onset breast cancer (age,50).
#OR adjusted for age at diagnosis, number of live births, age at menarche and menopause.
aassociated with low risk of breast cancer.
doi:10.1371/journal.pone.0057967.t007
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was 1.6 times higher (p = 0.03) and fbtA was 1.4 times higher
(p = 0.05) in Cases than in Controls in the African-American
cohort (Table 3). Logistic regression analysis performed in Cases
showed that African-American women with breast cancer were
more likely to have the FbTA (OR=2.4, p = 0.005) and FbtA
(OR=1.7, p = 0.04) haplotypes compared with Hispanic/Latina
women with breast cancer. In contrast to Cases, African-American
Controls with the fbTa (OR=0.8, p,0.001), fbTA (OR=0.8,
p = 0.03), fBTA (OR=0.8, p= 0.04) and fbtA (OR=0.7, p= 0.02)
haplotypes were significantly less frequently observed than among
Hispanic/Latina Controls.
Table 4 demonstrates the results from linkage disequilibrium
(LD) analysis performed on the four VDR variants. The strongest
LD is observed between VDR-TaqI and VDR-ApaI among
Hispanic/Latina subjects (D9=0.66). Weaker LDs were observed
between VDR-FokI and the other 3 variants (VDR-BsmI, VDR-ApaI
and, VDR-TaqI) in both African-American and Hispanic/Latinas.
The associations between the VDR genotypes and breast tumor
histopathology, tumor stage, and metastatic disease progression
were assessed in Table 5. The VDR-FokI FF genotype was
significantly more common in African-American patients than in
Hispanic/Latina patients (46.1% vs. 35.9%, respectively,
p = 0.02), while the VDR-FokI ff genotype was more common in
Hispanic/Latina patients as compared to African-American
patients (17.1% vs. 6.1%, respectively). African-American patients
were more likely to have VDR-ApaI AA genotype and Hispanic/
Latina patients were likely to have VDR-ApaI Aa or aa genotypes
(p = 0.008). There was also a significant association identified
between VDR-ApaI polymorphisms and tumor differentiation
(p = 0.04). Poorly differentiated tumors were more likely to express
a polymorphic allele of VDR-ApaI (Aa or aa). There were no other
significant associations found between any of the polymorphic
VDR variants and tumor stage, tumor differentiation, and ER/
PR/HER2 receptor status.
The 5-year disease-free-survival (DFS) from breast cancer in
association with VDR polymorphisms is shown in Figure 1. The 5-
year DFS in patients carrying VDR-FokI FF genotype is reduced
significantly compared to VDR-FokI Ff and ff genotypes (p = 0.05).
The VDR-BsmI, VDR-ApaI and VDR-TaqI polymorphisms did
not influence DFS significantly. Results of multivariate analyses,
adjusted for the tumor characteristics, ethnicity, and the four VDR
polymorphic variants, confirm the independent predictor value of
VDR-FokI in DFS as shown in Table 6. The relative risk of tumor
recurrence or metastases was decreased by 43% in patients who
had the polymorphic VDR-FokI alleles, Ff or ff, compared to
subjects who had VDR-FokI FF genotype (Table 6).
Discussion
The results from our study reveal an increased association
between one of the VDR polymorphic variants, VDR-FokI, and
breast cancer in the African-American cohort. The odds ratio
(OR) for breast cancer in association with the VDR-FokI f allele
was 1.9 (95% CI=0.9–3.7; p = 0.07). This is consistent with other
studies [25] which have identified a positive association between
the VDR-FokI ff genotype and/or f allele and breast cancer
(Table 7). Our study further identifies that this trend is present
among African-American women, but not Hispanic/Latina
women. The other most commonly studied VDR polymorphism,
VDR-BsmI, was not associated with breast cancer in our study,
similar to most of the other studies conducted on this polymor-
phism (Table 7). While Ingles et al [14] identified a significant
association of the B allele with breast cancer among Hispanics,
recent large studies and meta-analyses on various ethnic groups,
including Hispanics, have suggested otherwise. For example, the
large analyses conducted by Rollison et al [19] and Tang et al [10]
have confirmed that there is no significant association between
VDR-BsmI and breast cancer. Furthermore, data from our
current study shows no associations between the two other VDR
variants (TaqI and ApaI) and breast cancer, consistent with most
studies to date on Caucasian populations (Table 7). The VDR-
TaqI (tt genotype) and VDR-ApaI (a allele) were significantly
associated with breast cancer in only two hospital-based studies
[15,16]. However, these polymorphisms were found to be non-
significant in recent large population meta-analyses [10]. Linkage-
disequilibrium analysis of the polymorphisms in our study is also
consistent with findings from previous studies, confirming linkage
between VDR-TaqI and VDR-ApaI in Hispanic/Latina women,
and absence of LD between the VDR-FokI and other SNPs [6].
Additional studies on VDR SNPs [26–35] are presented in
Table 7. Abbas et al [26], suggested that VDR polymorphisms may
affect postmenopausal breast cancer risk, and be associated with
receptor status. Our study shows no receptor-specific association
(ER/PR/HER +/2) with any of the VDR polymorphic variants;
however, the VDR-ApaI aa genotype is significantly associated
with poorly differentiated tumors (p = 0.04). Since the VDR-ApaI
a allele is most common in Hispanic/Latinas, and the Latinas in
the present study were slightly younger than the African-American
subjects, these findings may potentially implicate VDR-ApaI in the
progression of cancer among younger breast cancer patients.
Further investigation among larger numbers of younger women
with breast cancer is necessary in order to discern a definite
association.
Lastly, recent reviews have concluded that the scientific evidence
between vitamin D status and breast cancer risk and outcome are
fairly strong, and improving vitamin D levels could improve health
status [36]. Unfortunately, studies to date which have utilized
vitamin D supplementation to overcome vitamin D insufficiency
have not yielded conclusive improvements in cancer health risks and
outcomes [37,38]. Hence examination of the Vitamin D receptor
(VDR), and genetic changes such as polymorphisms potentially
impacting VDR protein function may be central in identifying
confounding factors that play a role in Vitamin D activity and
ultimately patient outcome. Our study identifies that the 5-year
disease-free-survival from breast cancer is significantly reduced
among breast cancer patients with the VDR-FokI FF genotype (Log
rank= 6.06 and p=0.05). Cox regression with multivariate analysis
demonstrates the independently predictive value of VDR-FokI on
DFS. Hence, findings from our study suggest that while the VDR-
FokI f allele may play a role in early association with breast cancer
development, the F allele may play a role on tumor progression and
patient outcome. The findings on these VDR variants, together with
significant differences in haplotypes between Cases and Controls
suggest the potential need to screen for VDR polymorphisms in the
context of breast cancer, particularly before considering Vitamin D
supplementation.
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